Radiopharmaceutical developer Immunomedics has appointed Robert DeLuccia as CEO to take over duties previously handled by the company's founder, Dr. David Goldenberg. DeLuccia formerly served as marketing vice president at both Pfizer Laboratories and
Radiopharmaceutical developer Immunomedics has appointed Robert DeLuccia as CEO to take over duties previously handled by the company's founder, Dr. David Goldenberg. DeLuccia formerly served as marketing vice president at both Pfizer Laboratories and Winthrop Pharmaceuticals, as well as U.S. president of Sanofi Winthrop Pharmaceuticals.
DeLuccia will assume immediate management of the company, allowing Goldenberg to center his efforts on Immunomedics' cancer therapeutics research and other projects. DeLuccia's responsibilities will include developing strategies to best use the company's technology and personnel, according to the Morris Plains, NJ-based firm.
Immunomedics manufactures and distributes antibody-based cancer and infection imaging agents throughout the U.S. and Europe. Its products include CEA-Scan, for the detection of colorectal cancer, and LeukoScan, for the diagnosis of bone infection. LeukoScan is currently under review by the Food and Drug Administration.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.